A Tissue-Engineered Human Psoriatic Skin Model to Investigate the Implication of cAMP in Psoriasis: Differential Impacts of Cholera Toxin and Isoproterenol on cAMP Levels of the Epidermis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Jul 2020
Historique:
received: 11 06 2020
revised: 17 07 2020
accepted: 21 07 2020
entrez: 29 7 2020
pubmed: 29 7 2020
medline: 17 2 2021
Statut: epublish

Résumé

Pathological and healthy skin models were reconstructed using similar culture conditions according to well-known tissue engineering protocols. For both models, cyclic nucleotide enhancers were used as additives to promote keratinocytes' proliferation. Cholera toxin (CT) and isoproterenol (ISO), a beta-adrenergic agonist, are the most common cAMP stimulators recommended for cell culture. The aim of this study was to evaluate the impact of either CT or ISO on the pathological characteristics of the dermatosis while producing a psoriatic skin model. Healthy and psoriatic skin substitutes were produced according to the self-assembly method of tissue engineering, using culture media supplemented with either CT (10

Identifiants

pubmed: 32717879
pii: ijms21155215
doi: 10.3390/ijms21155215
pmc: PMC7432929
pii:
doi:

Substances chimiques

FLG protein, human 0
Filaggrin Proteins 0
Cholera Toxin 9012-63-9
Cyclic AMP E0399OZS9N
Adenylyl Cyclases EC 4.6.1.1
adenylate cyclase 9 EC 4.6.1.1
Isoproterenol L628TT009W

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : MOP-311262
Pays : Canada

Références

Curr Med Chem. 2017;24(28):3054-3067
pubmed: 28554321
J Pharmacol Exp Ther. 2004 Jul;310(1):108-15
pubmed: 14996950
Cell. 1978 Nov;15(3):801-11
pubmed: 83196
Exp Dermatol. 2018 May;27(5):512-519
pubmed: 29502346
Int Immunol. 2019 Aug 23;31(9):597-606
pubmed: 30926983
Arch Dermatol. 1971 Oct;104(4):352-8
pubmed: 4329804
J Invest Dermatol. 2017 Jan;137(1):123-131
pubmed: 27498346
Arch Dermatol. 2001 Mar;137(3):280-4
pubmed: 11255325
Diabetes Metab Syndr Obes. 2019 Dec 17;12:2685-2688
pubmed: 31908509
J Dermatol Sci. 1998 May;17(1):61-6
pubmed: 9651830
J Invest Dermatol. 1972 Jul;59(1):114-20
pubmed: 4339129
Biochem Biophys Rep. 2016 Sep 30;8:268-276
pubmed: 28955966
Actas Dermosifiliogr. 2009 Dec;100 Suppl 2:2-13
pubmed: 20096156
Int J Mol Sci. 2018 Jul 25;19(8):
pubmed: 30044428
J Invest Dermatol. 2007 Aug;127(8):2012-9
pubmed: 17429437
J Dermatol Sci. 2017 Oct;88(1):57-66
pubmed: 28571749
Burns. 1993 Apr;19(2):99-104
pubmed: 8471157
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
Tissue Eng Part C Methods. 2014 Jun;20(6):473-84
pubmed: 24188635
Int J Mol Sci. 2018 Sep 26;19(10):
pubmed: 30261611
J Invest Dermatol. 1983 Jul;81(1 Suppl):64s-8s
pubmed: 6306118
Exp Dermatol. 2011 Aug;20(8):627-32
pubmed: 21539622
Tissue Eng. 2006 Feb;12(2):245-55
pubmed: 16548683
Dermatology. 2019;235(2):91-100
pubmed: 30566935
Cell Div. 2013 Jan 03;8(1):1
pubmed: 23286511
Nat Rev Drug Discov. 2009 Apr;8(4):321-35
pubmed: 19337273
Nature. 2011 Jan 13;469(7329):241-4
pubmed: 21228877
N Engl J Med. 2005 May 5;352(18):1899-912
pubmed: 15872205
Dermatol Clin. 2007 Oct;25(4):643-53, x
pubmed: 17903623
Cell Signal. 2018 Nov;51:266-275
pubmed: 30121334
J Dermatol Sci. 2009 Jan;53(1):19-25
pubmed: 18783923
Nature. 2007 Feb 22;445(7130):866-73
pubmed: 17314973
Indian J Med Res. 2011 Feb;133:179-87
pubmed: 21415492
Horm Metab Res. 2012 Sep;44(10):713-5
pubmed: 22951901
J Biol Chem. 1988 Nov 15;263(32):17167-72
pubmed: 2460460
J Invest Dermatol. 1982 Jul;79(1):42-7
pubmed: 6177802
Exp Biol Med (Maywood). 2017 Jun;242(11):1158-1169
pubmed: 28585891
J Tissue Eng Regen Med. 2018 Apr;12(4):e2134-e2146
pubmed: 29377584
Cell Biochem Biophys. 2013 Jul;66(3):523-8
pubmed: 23283814
Br J Dermatol. 1978 Aug;99(2):197-200
pubmed: 698108
Biomed Mater. 2018 Mar 06;13(3):035008
pubmed: 29307874
Br J Dermatol. 1975 Jun;92(6):619-24
pubmed: 170954
Mediators Inflamm. 2015;2015:984690
pubmed: 26412948
J Invest Dermatol. 1975 Jul;65(1):170-8
pubmed: 239070
PLoS One. 2010 May 26;5(5):e10841
pubmed: 20520777
Clin Dermatol. 2012 May-Jun;30(3):323-8
pubmed: 22507047
Arch Dermatol Res. 1993;285(5):300-4
pubmed: 8397494
J Invest Dermatol. 1984 Apr;82(4):316-7
pubmed: 6323585
J Invest Dermatol. 2019 Nov;139(11):e133-e142
pubmed: 31648690
Biochim Biophys Acta. 1977 Apr 27;497(2):428-36
pubmed: 857911
J Allergy Clin Immunol. 1974 May;53(5):283-7
pubmed: 4362674
J Invest Dermatol. 1988 Aug;91(2):154-7
pubmed: 2456358
Arch Dermatol Res. 2004 Jul;296(2):74-82
pubmed: 15278365
J Invest Dermatol. 1978 May;70(5):250-3
pubmed: 205616

Auteurs

Mélissa Simard (M)

Centre de Recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 1Z4, Canada.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.

Sophie Morin (S)

Centre de Recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 1Z4, Canada.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.

Geneviève Rioux (G)

Centre de Recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 1Z4, Canada.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.

Rachelle Séguin (R)

Centre de Recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 1Z4, Canada.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.

Estelle Loing (E)

IFF-Lucas Meyer Cosmetics, Québec, QC G1V 4M6, Canada.

Roxane Pouliot (R)

Centre de Recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 1Z4, Canada.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH